Improving T-cell therapies for cancer treatment
Engineering bZIP family transcription factors for therapeutic T-cell persistence and effector function
['FUNDING_R37'] · BAYLOR COLLEGE OF MEDICINE · NIH-11114042
This work aims to make T-cell therapies more effective and long-lasting for people with cancer, especially those with solid tumors.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11114042 on ClinicalTrials.gov |
What this research studies
Cancer immunotherapy using specially engineered T cells shows great promise, but these cells often stop working well, especially in solid tumors. Our team is working to improve these T cells by changing specific genes that control their activity. We are exploring different ways to make T cells more resilient to the harsh conditions within tumors, helping them stay active longer and fight cancer more effectively. The goal is to find the best genetic modifications to create T cells that can clear tumors more successfully.
Who could benefit from this research
Good fit: This foundational research is for patients with cancer who may benefit from future advancements in T-cell immunotherapy.
Not a fit: Patients not seeking or eligible for T-cell based cancer therapies may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and durable T-cell immunotherapies for various cancers, particularly solid tumors that are currently difficult to treat.
How similar studies have performed: Preclinical models have shown improvements in tumor control with similar approaches, but this work seeks to clarify and optimize the best strategies.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FOIGHT, GLENNA WINK — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: FOIGHT, GLENNA WINK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.